Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022367030> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- W3022367030 endingPage "S31" @default.
- W3022367030 startingPage "S23" @default.
- W3022367030 abstract "Oncology biologics are one of the fastest-growing segments of pharmaceutical development, bringing more options to patients, including those with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The advent of multiple oncology biosimilars is affecting this patient population, as 5 trastuzumab biosimilars had been FDA approved as of the end of 2019; only 2, however, have been commercially marketed. Trastuzumab serves as the foundation for treatment for patients with HER2-positive breast cancer. HER2-targeted antibody-drug conjugates have been developed to enhance efficacy, improve safety, and/or create more convenient administration. Three biologic drug entities have been approved using trastuzumab, including 2 antibody-drug conjugates and a subcutaneous trastuzumab formulation that includes hyaluronidase. More products are being developed, so biosimilars and other HER2-targeted therapies may further disrupt the biologic market. Many challenging questions surround the adoption of oncology biosimilars, including regulatory pathways, efficacy, safety, cost-benefit, and comparability. The Biologics Price Competition and Innovation Act established an abbreviated regulatory approval pathway for biosimilars to create a catalyst for innovation and competition in the biologics market and to lower the costs of biologics. Challenges to adoption of therapeutic oncology biosimilars continue in the United States and include a lack of directed education to providers and patients, residual concerns regarding efficacy and safety, and practices including pay-for-delay. The uptake of oncology biosimilars is also affected by multiple issues stemming mainly from cost of care, including drug cost, patient access, formulary inclusion, and treatment management algorithms. Managed care organizations and payers need to be familiar with the biosimilar approval process, the concerns of stakeholders (eg, providers and patients), and factors influencing HER2-directed therapies, including the use of biosimilars and antibody-drug conjugates in today's market." @default.
- W3022367030 created "2020-05-13" @default.
- W3022367030 date "2020-03-01" @default.
- W3022367030 modified "2023-09-26" @default.
- W3022367030 title "Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies" @default.
- W3022367030 doi "https://doi.org/10.37765/ajmc.2020.42899" @default.
- W3022367030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32282172" @default.
- W3022367030 hasPublicationYear "2020" @default.
- W3022367030 type Work @default.
- W3022367030 sameAs 3022367030 @default.
- W3022367030 citedByCount "6" @default.
- W3022367030 countsByYear W30223670302021 @default.
- W3022367030 countsByYear W30223670302022 @default.
- W3022367030 crossrefType "journal-article" @default.
- W3022367030 hasConcept C121608353 @default.
- W3022367030 hasConcept C126322002 @default.
- W3022367030 hasConcept C143998085 @default.
- W3022367030 hasConcept C177713679 @default.
- W3022367030 hasConcept C2779786085 @default.
- W3022367030 hasConcept C530470458 @default.
- W3022367030 hasConcept C59491497 @default.
- W3022367030 hasConcept C71924100 @default.
- W3022367030 hasConcept C98274493 @default.
- W3022367030 hasConceptScore W3022367030C121608353 @default.
- W3022367030 hasConceptScore W3022367030C126322002 @default.
- W3022367030 hasConceptScore W3022367030C143998085 @default.
- W3022367030 hasConceptScore W3022367030C177713679 @default.
- W3022367030 hasConceptScore W3022367030C2779786085 @default.
- W3022367030 hasConceptScore W3022367030C530470458 @default.
- W3022367030 hasConceptScore W3022367030C59491497 @default.
- W3022367030 hasConceptScore W3022367030C71924100 @default.
- W3022367030 hasConceptScore W3022367030C98274493 @default.
- W3022367030 hasIssue "Suppl 2" @default.
- W3022367030 hasLocation W30223670301 @default.
- W3022367030 hasOpenAccess W3022367030 @default.
- W3022367030 hasPrimaryLocation W30223670301 @default.
- W3022367030 hasRelatedWork W2477982768 @default.
- W3022367030 hasRelatedWork W2761356983 @default.
- W3022367030 hasRelatedWork W2794649617 @default.
- W3022367030 hasRelatedWork W2794755138 @default.
- W3022367030 hasRelatedWork W2934222321 @default.
- W3022367030 hasRelatedWork W2947599283 @default.
- W3022367030 hasRelatedWork W3202363710 @default.
- W3022367030 hasRelatedWork W4287922124 @default.
- W3022367030 hasRelatedWork W4292478226 @default.
- W3022367030 hasRelatedWork W4297053010 @default.
- W3022367030 hasVolume "26" @default.
- W3022367030 isParatext "false" @default.
- W3022367030 isRetracted "false" @default.
- W3022367030 magId "3022367030" @default.
- W3022367030 workType "article" @default.